Annual ▼zoledronic acid for osteoporosis
Relevant BNF section: 6.6.2
▼Zoledronic acid (Aclasta – Novartis) is the first bisphosphonate to be licensed in the UK as a once-yearly intravenous treatment for women with postmenopausal osteoporosis.1 Promotional materials claim that the drug “provides powerful osteoprotection with yearlong compliance”, with “significant 3 year fracture reduction at all key sites”. Here we consider whether zoledronic acid has a role in the treatment of women with postmenopausal osteoporosis.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.